

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

APPOINTMENT OF VICE CHAIRLADY AND EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Consun Pharmaceutical**”) is pleased to announce that Ms. LI Qian (“**Ms. LI**”), an executive Director and the chief executive officer, has been appointed as the vice chairlady of the Board, and Mr. TANG Ning (“**Mr. TANG**”) has been appointed as an executive Director, both with effect from 1 June 2018.

These appointments enhance the Board’s leadership and also serve as preparations for the Group’s long-term development.

The biographies of Ms. LI and Mr. TANG are set out below:

Ms. LI Qian

Ms. LI, aged 53, an executive Director, the chief executive officer and one of the founders of the Group, and is also an executive director and the general manager of Guangxi Yulin Pharmaceutical Group Co., Ltd. (“**Yulin Pharmaceutical**”), a subsidiary of the Group. She is primarily responsible for strategy formulation and overall operation and management of the Group.

Ms. LI has over 27 years of experience in the business of pharmaceutical industry, with nearly 10 years of experience in medical education. Ms. LI worked at Southern Medical University from October 1989 to April 1998. Ms. LI joined the Group in 1997 when Consun Pharmaceutical was newly set-up, as the associate director of general manager’s office, human resources manager, deputy executive general manager and deputy sales general manager of Guangzhou Consun Pharmaceutical Company Limited (“**GZ Consun**”), a subsidiary of the Group. Ms. LI has also served as a director and the general manager (which was redesignated as president in May 2008) of GZ Consun since November 1999.

Ms. LI obtained a master’s degree in business administration at Asia International Open University (Macau) in November 2007. She has obtained 3 invention patents and published research papers on the “Chinese journal of Clinical Medicine” (《中國臨床醫學雜誌》). Ms. LI was awarded as Excellent Private Entrepreneur (優秀民營企業家) by Tongliao City People’s Government of the Inner Mongolia Autonomous Region in July 2008, and a Model Worker (勞動模範) by Inner Mongolia People’s Government in April 2010. In December 2010, she obtained the Third Prize for Technological Progress in the Inner Mongolia Autonomous Region (內蒙古自治區科技進步三等獎). In December 2011, she was recognised as Famous Entrepreneur in Pharmaceutical Industry of Guangdong Province (廣東省醫藥行業著名企業家) by Guangdong Province Pharmaceutical Industry Association (廣東省醫藥行業協會). In April 2014, she was elected as Chinese Pharmaceutical Brand Woman (中國(醫藥行業)品牌女性). In February 2017, she was accredited

as Excellent Entrepreneur in Pharmaceutical Industry of Guangdong Province (廣東省醫藥行業優秀企業家), in March 2017 obtained the First Prize for Technological Progress in Yulin City and in December 2017 was awarded the “Best Business Leader Award” by “China Finance”.

Ms. LI is a local registered pharmacist of Guangdong province (廣東省駐店藥師) recognised by Guangdong Food and Drug Administration (廣東省食品藥品監督管理局). Since March 2012, she has been appointed as a member of the First Expert Committee for Kidney Disease and Blood Purify of China Medical Women’s Association (第一屆中國女醫師協會腎臟病及血液淨化專家委員). In October 2014, she was elected as the deputy councillor of Expert Committee for Professional Committee of Chinese Medicine Product Development and Incubation of China Association of Traditional Chinese Medicine (中國中藥協會中藥產品開發與培育專業委員會). In August 2016, she was elected as the deputy councillor of the First Expert Committee for Chinese Medicine Development and Research for Kidney Disease of China Association of Traditional Chinese Medicine (中國中藥協會第一屆腎病中藥發展研究專業委員會), and a member of the Pharmacoeconomics Expert Committee (藥物經濟學專業委員會), and in July 2017 was elected as a member of the Standing Committee of the Encephalopathy Medicine Research Professional Committee of China Association of Traditional Chinese Medicine (中國中藥協會腦病藥物研究專業委員會).

Save as disclosed in this announcement, Ms. LI (i) has not held any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other position in the Company or any of its subsidiaries; (iii) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have other major appointments or professional qualifications.

Ms. LI has entered into a service agreement with the Company to act as an executive Director with a term of three years commencing from 19 December 2013, subject to the rotation provisions in accordance with the articles of association of the Company, and can be terminated by the Company or Ms. LI by giving not less than three months’ notice in writing or in other ways in accordance with the terms of the service agreement. According to Ms. LI’s service agreement with the Company, Ms. LI is entitled to RMB2,280,000 as annual salary as well as performance-based bonus. The terms of the service agreement of Ms. LI and the director’s emolument shall remain unchanged.

As at the date of this announcement, 5,865,261 ordinary shares of the Company are held by Ms. LI and 126,915,000 shares of the Company are held by Double Grace International Limited, which is wholly owned by Ms. LI. Ms. LI is also interested in 10,000,000 share options and, subject to the relevant terms of the share option scheme, may subscribe for 10,000,000 ordinary shares of the Company. Other than that, Ms. LI does not have, and/or is not deemed to have, any interest or short position in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong).

There are no other matters relating to the appointment of Ms. LI that need to be brought to the attention of the shareholders of the Company or to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Mr. TANG Ning

Mr. TANG, aged 52, is the vice president of GZ Consun. Mr. TANG joined the Group in July 1998 as a business manager. Between July 1998 and June 2011, Mr. TANG served various positions at GZ Consun, such as business manager, regional marketing manager, marketing and sales director, and president assistant. He has been the vice president of GZ Consun since June 2011. Prior to joining the Group, Mr. TANG worked in wholesale commercial trade of textiles products at Zhangjiajie City in Hunan Province between October 1987 and June 1998. Mr. TANG graduated from Hunan Business Management Cadre College (湖南商業管理幹部學院) in June 1986 with a major in marketing business economics.

Save as disclosed in this announcement, Mr. TANG (i) has not held any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other position in the Company or any of its subsidiaries; (iii) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have other major appointments or professional qualifications.

Mr. TANG has entered into a service agreement with the Company to act as an executive Director for a term of three years commencing from 1 June 2018, subject to the rotation provisions in accordance with the articles of association of the Company, and can be terminated by the Company or Mr. TANG by giving not less than three months' notice in writing or in other ways in accordance with the terms of the service agreement. According to the articles of association of the Company, Mr. TANG will retire from office at the forthcoming general meeting of the Company and be eligible for re-election. According to Mr. TANG's service agreement with the Company, Mr. TANG will receive a director's fee or emolument and performance-based bonus, which will be determined by the Board based on recommendation made by the Board's remuneration committee with reference to his performance in due course.

As at the date of this announcement, Mr. TANG is interested in 1,685,600 share options and, subject to the relevant terms of the share option scheme, may subscribe for 1,685,600 ordinary shares of the Company. Other than that, Mr. TANG does not have, and/or is not deemed to have, any interest or short position in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong).

There are no other matters relating to the appointment of Mr. TANG that need to be brought to the attention of the shareholders of the Company or to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to welcome Ms. LI as the vice chairlady of the Board and Mr. TANG for joining the Board.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 31 May 2018

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive directors.